SCA
ABBV icon

Sensenig Capital Advisors’s AbbVie ABBV Stock Holding History

Sensenig Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341K Sell
1,356
-100
-7% -$21.5K 0.31% 25
2026
Q1 		$317K Hold
1,456
– – 0.32% 26
2025
Q4 		$333K Buy
+1,456
New +$332K 0.34% 25

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sensenig Capital Advisors's ABBV Position: Q2 2026 in Review

Sensenig Capital Advisors reduced its AbbVie (ABBV) stake by 6.9% in Q2 2026, selling an estimated $21.5K and leaving 1,356 shares worth $341K. The position accounts for 0.31% of the portfolio, ranked #25.

Sensenig Capital Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sensenig Capital Advisors held 1,356 shares of AbbVie worth $341K as of Q2 2026.
  • Sensenig Capital Advisors sold 100 AbbVie shares in Q2 2026, an estimated $21.5K.
  • AbbVie made up 0.31% of Sensenig Capital Advisors's portfolio in Q2 2026, its #25 holding.
  • Sensenig Capital Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sensenig Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.